Skip to main content
. 2017 Feb 16;8(20):33922–33932. doi: 10.18632/oncotarget.15412

Figure 3. Meta-analysis of the prognosis of circulating EGFR mutations for PFS.

Figure 3

A. Forest plots of HR and 95% CI in advanced NSCLC patients. Patients with circulating EGFR mutations had a better PFS (HR = 0.64, 95% CI 0.51-0.81); B. results of sensitive analysis showed that there was no “dominant” study driving the results of the meta-analysis; C. forest plots of HR and 95% CI in advanced NSCLC patients treated by EGFR-TKIs. Circulating EGFR mutations indicated a better PFS among patients who were treated by EGFR-TKIs (HR = 0.64, 95% CI 0.51-0.81).